Immunogenetic Profiling of Dupilumab for the Treatment of Atopic Dermatitis

Inclusion Criteria: * Ability to provide written informed consent and comply with the protocol. * At least 18 years of age. * Diagnosis of chronic atopic dermatitis for at least 3 years prior to enrollment. * Subject is considered a candidate for phototherapy or systemic therapy * Eczema Area and Severity Index (EASI) score ≥ 12 * Investigator Global Assessment (IGA) ≥ 3 * 10% body surface area (BSA) or greater * Subject is unlikely to conceive due to male, post-menopausal, or using adequate contraceptive (barrier, hormonal, implant, or permanent sterilization methods). * Physical exam within clinically acceptable limits. Exclusion Criteria: * Subject is unable to provide written informed consent or comply with the protocol. * Subject is younger than 18 years of age. * Subject has had atopic dermatitis for less than 3 years prior to enrollment. * Subject with mild atopic dermatitis (EASI\<12 and IGA\<3) or is not a candidate for phototherapy or systemic treatments. * Subject with current, or a history of, severe atopic dermatitis well controlled on current therapy. * Serious known infection. * History of immunosuppression (including human immunodeficiency virus (HIV)) * History of malignancy within 5 years before the screening visit, except completely treated in situ carcinoma of the cervix, completely treated and resolved non-metastatic squamous or basal cell carcinoma of the skin. * Severe concomitant illnesses. * Having used immunosuppressive/immunomodulating drugs (eg,…